Skip to main content
. 2021 May 8;5(2):177–201. doi: 10.1007/s41885-021-00083-6

Table 1.

Risks and Costs Associated with a COVID Infection

Age Group
0-19 20-44 45-54 55-64 65-74 75-84 ≥ 85
% of US population 25% 33% 13% 13% 9% 5% 2%
OUTCOME PROBABILITIES
Clinical outcomes
Prob. of hospitalization 1.29% 2.27% 4.23% 6.17% 13.96% 22.34% 60.00%
Probability of dying (IFR) 0.003% 0.020% 0.423% 0.500% 2.500% 8.500% 28.300%
Outcomes for symptomatic patients
Proportion high-risk 8% 15% 24% 33% 51% 51% 51%
Outpatient visit
- low-risk patients 32% 32% 32% 31% 62% 62% 62%
- high-risk patients 77% 63% 63% 63% 82% 82% 82%
COST ESTIMATES
Case not medically attended
Medical cost (all risk) $5 $5 $5 $5 $5 $5 $5
Lost productivity (all risk) $260 $260 $260 $260 $520 $520 $520
Outpatient visit
Low-risk medical cost $161 $212 $233 $254 $410 $410 $410
Low-risk lost productivity $520 $520 $780 $1,040 $1,560 $1,560 $1,560
High-risk medical cost $1,098 $1,227 $1,234 $1,240 $806 $806 $806
High-risk lost productivity $2,080 $1,040 $1,560 $2,080 $3,640 $3,640 $3,640
Hospitalization
Low-risk medical cost $25,408 $32,174 $34,960 $37,745 $19,379 $19,379 $19,379
Low-risk lost productivity $4,680 $6,240 $6,500 $6,760 $6,760 $6,760 $6,760
High-risk medical cost $70,938 $80,760 $75,334 $69,908 $28,346 $28,346 $28,346
High-risk lost productivity $11,960 $10,920 $11,700 $12,480 $9,360 $9,360 $9,360
Fatalities
Low-risk lost productivity $4,680 $6,240 $6,500 $6,760 $6,760 $6,760 $6,760
High-risk lost productivity $11,960 $10,920 $11,700 $12,480 $9,360 $9,360 $9,360
Value of statistical life ($, mil.) 5.76 12.34 10.05 7.75 5.29 5.29 5.29

SOURCES For hospitalization risks: (Reese et al. 2020) and CDC; for IFR: (Levin et al. 2020) and CDC’s “COVID-19 Pandemic Planning Scenarios,” Scenario 5; for high- and low-risk probabilities and cost estimates: (Molinari et al. 2007) and (CEA 2019); for productivity losses: (Molinari et al. 2007) and (Barrot et al. 2020); for VSL: (Aldy and Viscusi 2008) and (CEA 2019); author’s calculations

NOTES This table presents the risks and per-person medical risks and productivity costs associated with various outcomes of the COVID-19 infection